The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy. Cabozantinib was administered in dose 60 mg/day, a subset of patients received initial dose of 40 mg/day.
Although testicular germ cell tumor (TGCT) overall is highly curable, patients may experience late effects after treatment. An increased understanding of the mechanisms behind the development of TGCT may pave the way for better outcome for patients.
We report a case using combination cabozantinib/nivolumab to salvage disease control in a patient with refractory metastatic renal cell carcinoma (mRCC). The patient had previously experienced disease progression from high dose IL-2, sunitinib, pazopanib, cabozantinib, and nivolumab, all given sequentially.
Optimal patient stratification is critical in the era of personalized medicine. Germline polymorphisms play an important role in the treatment response of various human diseases, including bladder cancer.
While the immediate care and access disruptions associated with the COVID-19 pandemic have received growing attention in certain areas, the full range of gaps in cancer screenings and treatment is not yet well understood or well documented throughout the country comprehensively.
Metastatic urothelial carcinoma (mUC) remains a fatal malignancy, despite the recent addition of immune check point inhibitors (ICIs), an FGFR inhibitor and an antibody-drug conjugate (ADC) to the therapeutic armamentarium.
Radical nephroureterectomy (RNU) is the standard treatment for patients with upper tract urothelial carcinoma (UTUC). However, approximately 25% of patients experience recurrence or metastasis after RNU.
Emerging evidence has shown the impact of the microbiome on solid organ malignancies such as gastric (H. pylori) and cervical cancer (HPV). Thus, a clinically relevant question would be whether the urinary microbiome has any effect on bladder carcinogenesis and whether specific microbial profiles can help prognosticate disease outcomes. Another provocative consideration is whether its […]
In our article, “Optimal Modeling: an Updated Method for Safely and Effectively Eliminating Curvature During Penile Prosthesis Implantation,” we provide an analysis of a modern adaption of a well-established technique for correction of penile curvature. First described by Wilson and Delk in 1994, manual modeling during penile prosthesis insertion is a known treatment for men […]
San Francisco, CA (UroToday.com) — The U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) – the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.
